1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Building on Prostate Cancer Working Group 2 to change the paradigm from palliation to cure
    Journal Article

    Scher, H. I.
    American Society of Clinical Oncology Educational Book (2014)

    Fulltext@MSK | Save
  • Beyond stage I germ cell tumors: Current status regarding treatment and long-term toxicities
    Journal Article

    Haugnes, H. S.; Stephenson, A. J.; Feldman, D. R.
    American Society of Clinical Oncology Educational Book (2014)

    Fulltext@MSK | Save
  • Oncogenic RAF mutants that signal as functional dimers are resistant to current RAF inhibitors but sensitive to a novel inhibitor of RAF dimer kinase activity
    Meeting Abstract

    Yao, Z.; Torres, N. M.; Wei, M.; Hanrahan, A.; Abdel-Wahab, O.; Solit, D.; Luo, L.; Poulikakos, P.; Rosen, N.
    Molecular Cancer Research (2014)

    Fulltext@MSK | Save
  • Comprehensive molecular profiling of urothelial bladder cancer at the DNA, RNA, and protein levels: A TCGA project
    Meeting Abstract

    Weinstein, J. N.; Kim, J.; Creighton, C. J.; Akbani, R.; Hoadley, K. A.; Kim, W. Y.; Morgan, M. B.; Hinoue, T.; Rosenberg, J. E.; Bajorin, D. F.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Identification and validation of predictive biomarkers (BM) for everolimus (EVE) in metastatic renal cell carcinoma: Analysis of 442 patients on RECORD-3
    Meeting Abstract

    Voss, M. H.; Chen, D.; Marker, M.; Hamilton, M.; Kalfoglou, C.; Hsieh, J.; Knox, J. J.; Anak, O.; Motzer, R. J.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • First-in-human phase I "basket" study of Debio1347 (CH5183284), a novel FGFR inhibitor, in patients FGFR genoinically activated advanced solid tumors
    Meeting Abstract

    Voss, M. H.; Adamo, B.; Heist, R. S.; Gandhi, L.; Moulon, C.; Tanaka, H.; Ishii, N.; Vasiln, A.; Aoki, Y.; Nicolas-Metral, V.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Establishing a neoadjuvant platform for developing targeted agents: Degarelix prior to prostatectomy for patients with intermediate- and high-risk prostate cancer
    Meeting Abstract

    Touijer, K. A.; Carver, B. S.; Coleman, J. A.; Laudone, V. P.; Hullings, M.; Ehrlich, S. S.; DeNunzio, M.; Reuter, V. E.; Eastham, J. A.; Danila, D. C.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors
    Meeting Abstract

    Sonpavde, G.; Bellmunt, J.; Rosenberg, J. E.; Bajorin, D. F.; Regazzi, A. M.; Choueiri, T. K.; Qu, A. Q.; Niegisch, G.; Albers, P.; Necchi, A.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Clinical and histologic characterization of dermatologic adverse events front the pan-PI3K inhibitor buparlisib (BKM-120)
    Meeting Abstract

    Schindler, K.; Abraham, R.; Shah, P. D.; Chandarlapaty, S.; Paik, P. K.; Bell-Mcguinn, K.; Bajorin, D. F.; Mellinghoff, I. K.; Younes, A.; Gounder, M. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Circulating tumor cells (CTCs) and LDH as prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial
    Meeting Abstract

    Scher, H. I.; Fizazi, K.; Lee, C.; Maclean, D.; Tejura, B.; Webb, I. J.; Borgstein, N.; Dreicer, R.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save